Results 201 to 210 of about 24,058 (227)
Some of the next articles are maybe not open access.
Current opinion in investigational drugs (London, England : 2000), 2003
Avinza is a once-daily morphine sulfate controlled-release formulation utilizing SODAS (Spheroidal Oral Drug Absorption System) technology developed by Elan and Ligand for the potential treatment of pain [220806], [223862]. This multiparticulate product is designed to provide a rapid onset of action together with a sustained therapeutic effect over 24 ...
openaire +1 more source
Avinza is a once-daily morphine sulfate controlled-release formulation utilizing SODAS (Spheroidal Oral Drug Absorption System) technology developed by Elan and Ligand for the potential treatment of pain [220806], [223862]. This multiparticulate product is designed to provide a rapid onset of action together with a sustained therapeutic effect over 24 ...
openaire +1 more source
A novel ELANE variant causing severe congenital neutropenia diagnosed in adulthood.
Blood Cells, Molecules & DiseasesR. Cerqueira +4 more
semanticscholar +1 more source
De Novo Deep Intron ELANE Mutation Resulting in Severe Congenital Neutropenia
Journal of Clinical ImmunologyZ. Shu +3 more
semanticscholar +1 more source
The Spectrum of ELANE Mutations and Their Implications in Severe Congenital and Cyclic Neutropenia
Human Mutation, 2013Matthias Ballmaier +2 more
exaly
Ziconotide (Elan Pharmaceuticals).
IDrugs : the investigational drugs journal, 2005Elan Pharmaceuticals (formerly Neurex) is developing ziconotide, a neuron-specific N-type calcium channel blocker, for the potential treatment of severe pain and ischemia. A US NDA for the use of the compound in intractable pain is under review [351606,357600] and phase III trials for ischemia are ongoing [261455,292579].
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2004
Natalizumab is a humanized monoclonal antibody to alpha 4 beta 1 integrin (VLA-4) currently under development by Elan and Biogen for the treatment of Crohn's disease and multiple sclerosis. Phase II trials in both indications have been completed, and by December 2002 phase III trials in Crohn's disease and multiple sclerosis had been initiated.
openaire +1 more source
Natalizumab is a humanized monoclonal antibody to alpha 4 beta 1 integrin (VLA-4) currently under development by Elan and Biogen for the treatment of Crohn's disease and multiple sclerosis. Phase II trials in both indications have been completed, and by December 2002 phase III trials in Crohn's disease and multiple sclerosis had been initiated.
openaire +1 more source

